Article
A Replication‐Defective Myxoma Virus Inducing Pro‐Inflammatory Responses as Monotherapy and an Adjuvant to Chemo‐ and DC Immuno‐Therapy for Ovarian Cancer
2025-06-02
Abstract excerpt
Myxoma virus (MYXV), a rabbit specific poxvirus and non-pathogenic to humans and mice, is an excellent candidate oncolytic virus for cancer therapy. MYXV also has immunotherapeutic benefits. In ovarian cancer (OC), immunosuppressive tumor associated macrophages (TAMs) are key to inhibit antitumor immunity while hindering therapeutic benefit by chemotherapy and dendritic cell (DC) vaccine. Because MYXV favors bindi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 980e1cea-f647-5f9b-95f4-08e8e5e3383b
- DOI
- 10.20944/preprints202506.0004.v1
